Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MGLL | Q99685 | 7/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 2/20 | 0.44 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13363263 | 0.75 | HTR3A (0.76) | MGLLHTR3APARP1 | |
| SCHEMBL29520225 | 0.74 | HTR3A (0.74) | MGLLHTR3APARP1 | |
| SCHEMBL20897471 | 0.73 | MGLL (1.00) | MGLL | |
| SCHEMBL1018884 | 0.72 | ALDH1A1 (0.53) | ALDH1A1HPGDMGLLHTR3ASMN1; SMN2 | |
| SCHEMBL30850864 | 0.71 | HTR3A (1.00) | ALDH1A1MGLLHTR3AMAPT | |
| SCHEMBL23576917 | 0.71 | TUBB4A (0.69) | ALDH1A1SMN1; SMN2LMNAKDM4ESTAT3 | |
| SCHEMBL30013860 | 0.71 | TUBB4A (0.69) | ALDH1A1SMN1; SMN2LMNAKDM4ESTAT3 | |
| SCHEMBL12004307 | 0.70 | CSNK2A1 (0.55) | ALDH1A1HPGDMGLLHTR3ASMN1; SMN2 | |
| SCHEMBL20897573 | 0.70 | HTR3A (0.72) | MGLLHTR3APARP1 | |
| SCHEMBL23749976 | 0.69 | PARP1 (0.61) | ALDH1A1SMN1; SMN2LMNAKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507776-B1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7119111-B2 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | ALDH1A1 271/4885HPGD 24/4885MGLL 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.